Novartis is paying $2B upfront to acquire Pikavation Therapeutics (a Synnovation Therapeutics subsidiary) for its pan-mutant selective PI3Kα inhibitor portfolio led by oral SNV4818, now in Phase I/II for breast cancer and other advanced solid tumors. The bet: mutant-selective PI3Kα targeting that spares wild-type enzyme could improve tolerability and enable more consistent dosing and combinations versus earlier-generation PI3Kα inhibition.

Why It Matters To Oncology

• PIK3CA-mutant signaling is a validated driver in HR+/HER2- breast cancer, but tolerability has limited how hard—and how long—clinicians can push pathway inhibition.

• SNV4818 is designed to hit mutated PI3Kα while sparing wild-type PI3Kα in healthy cells, aiming to reduce on-target/off-tumor toxicities that can force dose reductions or discontinuation.

• Novartis positions the oral profile as supportive of earlier-line combination strategies, including with hormonal therapy and CDK inhibitors.

• The acquisition adds a next-wave approach alongside an already competitive class landscape that includes Novartis’ Piqray (alpelisib) and Roche’s Itovebi (inavolisib) in PIK3CA-mutant HR+/HER2- breast cancer.

The Financials

• $2B upfront from Novartis to acquire Pikavation Therapeutics.

• Up to $1B more in development, regulatory, and commercial milestones.

• Transaction expected to close in the first half of 2026.

• Deal echoes Eli Lilly’s prior move for Scorpion’s mutant-selective PI3Kα program (up to $2.5B), centered on oral STX-478 (then Phase I/II).

What They're Saying

• Novartis development president Shreeram Aradhye: mutated PI3Kα is a “well-established driver” in HR+/HER2- breast cancer, but “there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile.”

• Aradhye on SNV4818: it “applies new mutant-selective chemistry” to better spare normal cells, with potential for “improved tolerability and more durable benefit…through precision medicine.”

What's Next

• Readouts to watch from the ongoing Phase I/II SNV4818 study in breast cancer and other advanced solid tumors: dose optimization, discontinuation rates, and early combination feasibility.

• Competitive bar-setting will come from how SNV4818 differentiates versus approved PI3Kα inhibitors (and other mutant-selective entrants) on tolerability at biologically active exposure.

• Integration and portfolio strategy post-close: which tumor types and combination regimens Novartis prioritizes to expand beyond current PIK3CA-mutant HR+/HER2- paradigms.